VKTX — Viking Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1607678 ·
Last close
$26.88
Market Cap
$3.43B
52W High
$43.10
52W Low
$23.82
ADV30
4,606,357
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 0 | — | -132,597,000 | -128,022,000 | 521,898,000 | 125,750,000 | 113,581,000 |
| Mar 2026 | 0 | — | -164,125,000 | -158,325,000 | 608,242,000 | 118,116,000 | 106,325,000 |
| Dec 2025 | 0 | — | -164,738,000 | -157,662,000 | 715,729,000 | 165,810,000 | 76,667,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-462,632,000
Investing CF
$331,751,000
Financing CF
$708,317,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.40
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,317,079,000
Inventory
—
Receivables
—
ST Investments
$282,204,000
EBIT TTM
$-644,558,000
Pretax Income TTM
$-627,195,000
Interest Exp TTM
$88,000
Analysts
19
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -393,342,000 | -359,639,000 | 715,729,000 | 76,667,000 | 639,062,000 | -278,685,000 |
| Dec 2024 | 0 | -150,921,000 | -109,963,000 | 908,321,000 | 28,043,000 | 880,278,000 | -87,790,000 |
| Dec 2023 | 0 | -100,827,000 | -85,895,000 | 368,490,000 | 20,071,000 | 348,419,000 | -73,376,000 |
| Dec 2022 | 0 | -70,355,000 | -68,867,000 | 168,529,000 | 23,207,000 | 145,322,000 | -48,397,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-534,796,000
OpCashFlow TTM
—
Assets (Latest)
$521,898,000
Forward EPS
$-5.08
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $27.50 · spot: $26.17 · call volume: 320 · put volume: 1,391
Expected Move to 2026-12-18:
±$5.11
(19.53%) —
implied range
$21.06 –
$31.28
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc.\DE | $3.41B | $30.06 | — |
| ELVN | Enliven Therapeutics, Inc. | $3.45B | $46.85 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.46B | $27.33 | — |
| IRON | Disc Medicine, Inc. | $3.49B | $76.57 | — |
| PBLS | Parabilis Medicines, Inc. | $3.49B | $28.25 | — |
News headlines (Yahoo Finance, 1h cache)
Learn Why The Bull Case For Viking Therapeutics Stock Could Change Following Obesity Drug Trial Progress
2026-11-18 21:09 · Yahoo
Viking Therapeutics Eyes 2029 Obesity Drug Launch, Tests Less-Frequent Dosing
2026-11-18 18:14 · Yahoo
Have $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.
2026-11-18 13:20 · Yahoo
Viking: 3 Key Takeaways for Long-Term Investors
2026-11-17 05:29 · Yahoo
Should You Trim Or Add To Your Viking Therapeutics Position?
2026-11-16 19:46 · Yahoo
Viking's Obesity Drug in Competitive Position Ahead of Phase 3 Readout, Oppenheimer Says
2026-11-16 18:55 · Yahoo
VKTX Stock Gives Back Buyout Speculation-Spurred Gains, Investors Continue To Await Key Obesity Trial Topline Data
2026-11-16 18:50 · Yahoo
Why Did Viking Therapeutics Stock Jump?
2026-11-16 11:42 · Yahoo
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
2026-11-15 17:05 · Yahoo
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
2026-11-13 09:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.